

## Registration and Lunch Buffet (Sala Polivalente)

**CONFERENCE OPENING**

**Sofia Avnet** (*Bologna - Italy*)

14.00-14.15 Opening

14.15-14.45 **Opening lecture** – The tumor microbiome, an important component of the tumor microenvironment. **Ravid Straussman** (*Rehovot - Israel*)

**SESSION 1. MICROENVIRONMENT AND CANCER METABOLISM**

**Holger Becker** (*Hannover - Germany*)

**Silvia Lemma** (*Bologna - Italy*)

15.00-15.15 Stromal uptake and transmission of acid is a pathway for venting cancer cell. **Hulikova A, Black N, Hsia LT, Wilding J, Bodmer WF, Swietach P** (*Oxford, United Kingdom*)

15.15-15.30 Lactate shuttling as a fuel for osteolytic activity in giant cell tumor of bone. **Lemma S, Avnet S, Errani C, Donati DM, Baldini N** (*Bologna - Italy*)

15.30-15.45 Blockade of glutamine synthetase skews macrophages towards a M1-like phenotype and inhibits tumor metastasis. **Castegna A, Menga A, Palmieri EM** (*Bari - Italy*)

15.45-16.00 The IKB kinase E links the innate immune response with serine and Warburg metabolism in breast cancer. **Xu R, Jones W, Wilcz-Villega E, Rajeeve V, Nagano A, De Costa S, Chelala C, Cutillas P, Frezza C, Bianchi K** (*London, United Kingdom*)

16.00-16.15 Interactions via tunneling nanotubes and transfer of mitochondria between mesenchymal stem cells and target cancer cells effects on metabolism and biological function. **Nakhle J, Gerbal-Chaloin S, Daujat-Chavanieu M, Hugnot JP, Charlot B, Vignais ML** (*Montpellier, France*)

16.15-16.30 Role of microenvironment on metabolism and migration of a SDHB silenced pheochromocytoma cell line on metabolism and biological function. **Martinelli S, D'Antongiovanni V, Richter S, Canu L, Pacak K, Eisenhofer G, Mannelli M, Rapizzi E** (*Florence, Italy*)

16.30-16.45 Mitochondria as CAF-fuelled powerhouse in prostate carcinoma cells. **Ippolito L, Morandi A, Comito G, Taddei ML, Iscaro A, Parri M, Masquelier J, Muccioli GG, Sonveaux P, Giannoni E, Chiarugi P** (*Florence, Italy*)

Coffee Break (Sala Cagliari)

Conference rooms  
for DAY 1

- > 14.00 Opening:  
Chiesa
- > 15.00 Session 1:  
Sala Affrescata
- > 15.00 Session 2:  
Sala Museo
- > 17.00 Session 3:  
Sala Affrescata
- > 17.00 Session 4:  
Sala Museo
- > 18.15 Session 5:  
Sala Museo

**SESSION 2. METABOLIC CONTROL OF CANCER STEMNESS****Stephan Reshkin** (*Bari - Italy*)**Alessandro Carrer** (*Philadelphia- USA*)

15.00-15.15 Role of ECM collagen I levels in regulating PDAC parenchymal cell (CPC) and cancer stem cell (CSC) metabolic plasticity-3. **Valente D, Greco MR, Baltazar F, Queirós O, Cannone S, Cardone RA, Reshkin SJ** (*Bari - Italy*)  
**EACR sponsored lecture**

15.15-15.30 ATP-citrate lyase links metabolism and histone modification during pancreatic tumorigenesis. **Carrer A, Trefely S, Parris J, Sela Y, Norgard R, Garcia BA, Blair IA, Snyder NW, Stanger BZ, Wellen KE** (*Philadelphia - USA*)  
**Sprint Bioscience Travel grant**

15.30-15.45 Prominent role of RAB39A-RXRB axis in cancer development and stemness. **Chano T, Kita H, Avnet S, Lemma S, Baldini N** (*Shiga, Japan*)

15.45-16.00 The metabolic profile of chronic myeloid leukaemia stem cell subsets as a target to suppress treatment-resistant minimal residual disease. **Poteti M, Cheloni G, Lulli M, Mazure NM, Rovida E, Dello Sbarba P** (*Florence, Italy*)

16.00-16.15 V-ATPase control of EVs signaling in glioma stem cells on metabolism and biological function. **Bertolini I, Terrasi A, Bosari S, Vaira V** (*Milan, Italy*)

16.15-16.30 3D interactions between tumor cells and mesenchymal stroma are crucial for cancer stemness, invasiveness, and chemoresistance. **Cortini M, Avnet S, Baldini N** (*Bologna, Italy*)

16.30-16.45 Notch signalling in orofacial cancers. **Mitsiadis T** (*Zurich, Switzerland*)

Coffee Break (Sala Cagliari)

**SESSION 3. PH DYNAMICS AND CA-9 TARGETING****Silvia Pastorekova** (*Bratislava - Slovakia*)**Russell Shonagh** (*Tampa - USA*)

17.15-17.30 Ectodomain cleavage of carbonic anhydrase IX affects tumorigenic behavior of cancer cells. **Zatovicova M, Vidlickova I, Jelenska L, Kopacek J, Pastorekova S** (*Bratislava - Slovakia*)

17.30-17.45 Protons: The driving force in cancer metastasis? **Shonagh R, Xu L, Gillies RJ** (*Tampa - USA*)  
**Nikon Travel grant**

[www.iscams.org](http://www.iscams.org)Conference rooms  
for DAY 1

- > 14.00 Opening:  
Chiesa
- > 15.00 Session 1:  
Sala Affrescata
- > 15.00 Session 2:  
Sala Museo
- > 17.00 Session 3:  
Sala Affrescata
- > 17.00 Session 4:  
Sala Museo
- > 18.15 Session 5:  
Sala Museo

- > 14.00 Opening:  
Chiesa
- > 15.00 Session 1:  
Sala Affrescata
- > 15.00 Session 2:  
Sala Museo
- > 17.00 Session 3:  
Sala Affrescata
- > 17.00 Session 4:  
Sala Museo
- > 18.15 Session 5:  
Sala Museo

- 17.45-18.00 Voltage gated proton channels as essential structures in leukemic Jurkat  
O17 T cell pH homeostasis and survival. **Asuaje A, Enrique N, Martin P, Orlowsky A, Aiello EA, Smaldini P, Docena G, Milesi V** (*La Plata - Argentina*) Promega Travel grant
- 18.00-18.15 Extracellular acidosis triggers a senescence-like phenotype associated  
O18 with reprogramming in human melanoma cells. **Boehme I, Bosserhoff AK** (*Erlangen, Germany*)
- 18.15-18.30 Functional relationships between ion channels and pH-regulating mecha-  
O19 nisms in colorectal cancer. **lorio J, D'Amico M, Arcangeli A** (*Florence, Italy*)
- 18.30-18.45 Extracellular carbonic anhydrase IX supports transport activity of MCTs  
O20 by direct interaction. **Ames S, Jamali S, Becker HM** (*Hannover, Germany*)
- 18.45-19.00 Depletion of CA IX impairs glutamine and glucose driven fueling of the  
O21 TCA cycle. **Panisova E, Sedlakova O, Kery M, Porporato PE, Brisson L, Sboarina M, Lacinová P, Škultéty L, Kopáček J, Pastorekova S, Sonveaux P, Svastova E** (*Bratislava, Slovakia*)
- 19.00-19.15 Intratumoral acidosis supports cancer aggressiveness in bone metasta-  
O22 sis. **Di Pompo G, Lemma S, Baldini N, Avnet S** (*Bologna, Italy*)
- 19.15-19.30 Clinical trial of radiotherapy after intravenous injection of acridine orange  
O23 for cancer patients: First report. **Kusuzaki K, Yoshimura H, Kitano S, Takai S** (*Nara, Japan*)

Welcome Cocktail and Dinner

#### SESSION 4. AUTOPHAGY AND LYSOSOMES

**Angelo De Milito** (*Stockholm, Sweden*)

**Mila Gugnoni** (*Reggio Emilia, Italy*)

- 17.15-17.30 Cadherin-6 promotes EMT and cancer metastasis by restraining  
O24 autophagy. **Gugnoni M, Sancisi V, Gandolfi G, Manzotti G, Ragazzi M, Giordano D, Tamagnini I, Tigano M, Frasoldati A, Piana S, Ciarrocchi A** (*Reggio Emilia, Italy*)

- 17.30-17.45 Autophagy and VPS34 as novel targets in anti-cancer therapy. **Yu Y, Dyczynski M, Parpal S, Braga T, Hägg-Olofsson M, Pokrovskaja Tamm K, De Milito A, Grandér D** (*Stockholm, Sweden*)

- 17.45-18.00 ROS levels and cell death are increased in T-all cells by mTORC inhibi-  
O26 tion. **Raimondi V, Micol Silic-Benussi M, Linseisen M, Urso L, Cavalari I, Minuzzo S1, del Bianco P1, Scattolin G2, Rende F2, Basso G3, Indraccolo S, D'Agostino DM, Ciminale V** (*Padua, Italy*)

**18.00-18.15** PIK3C2G loss promotes pancreatic cancer through mTOR regulation and metabolic rewiring. **Martini M, Ratto E, De Santis MC, Wyart E, Fan F, Cappello P, Porporato PE, Hirsch E** (*Turin, Italy*)  
**O27**

### SESSION 5. LIPID METABOLISM

**Cyril Corbet** (*Brussels, Belgium*)

**Karin Bartel** (*Munich, Germany*)

**18.15-18.30** The phospholipase DDHD1 is a new target for the development of anti-tumor therapies in colorectal cancer. **Raimondo S, Cristaldi M, Fontana S, Saieva L, Monteleone F, Conigliaro A, Zito G, Alessandro R** (*Palermo, Italy*)  
**O28**

**18.30-18.45** Targeting lipid metabolism in cancer cells by inhibiting the V-ATPase. **Bartel K, Winzi M, Ulrich M, Koeberle A, Menche D, Werz O, Müller R, Guck J, Vollmar AM, von Schwarzenberg K** (*Munich, Germany*)  
**O29**

**18.45-19.00** Investigation of lipidome perturbations caused by anti-VEGF treatment in ovarian cancer xenografts. **Venturoli C, Ferrazza R, Verza M, Curta-rella M, Grassi A, Guella G, Indraccolo S** (*Padua, Italy*)  
**O30**

**19.00-19.15** Liver PGC-1 $\beta$  drives mitochondrial signatures that contributes to hepatocellular carcinoma development. **Piccinin E, Peres C, Bellafante E, Villani G, Moschetta A** (*Bari, Italy*)  
**O31**

Welcome Cocktail and Dinner

[www.iscams.org](http://www.iscams.org)

Conference rooms  
for DAY 1

- > 14.00 Opening:  
Chiesa
- > 15.00 Session 1:  
Sala Affrescata
- > 15.00 Session 2:  
Sala Museo
- > 17.00 Session 3:  
Sala Affrescata
- > 17.00 Session 4:  
Sala Museo
- > 18.15 Session 5:  
Sala Museo

**SESSION 6. MITOCHONDRIA IN CANCER****Annamaria Porcelli** (Bologna, Italy)**Ivana Kurelac** (Bologna, Italy)**8.30-8.45** MYC induces the mTORC1 regulator TSC1 for mitochondrial homeostasis**O32** and tumour maintenance in Burkitt's lymphoma. **Hartleben G, Müller C, Krämer A, Schimmel H, Zidek LM, Dornblut C, Winkler R5, Eichwald S, Kortman G, Kosan C, Kluiver J, Petersen I, van den Berg A, Wang ZQ, Calkhoven CF** (Neuherberg, Germany)**8.45-9.00** Mitochondrial reactive oxygen species prime T-all cells to apoptosis by engaging the OMA1-OPA1 axis. **Scattolin G, Silic-Benussi M, Cavallari I, Minuzzo S, Francescato S, del Bianco P, Basso G3, Indraccolo S, D'Agostino DM, Ciminale V** (Padua, Italy)**9.00-9.15** Utilising the re-purposed antidepressant clomipramine to elicit mitochondrial-mediated apoptosis in human glioblastoma cells. **Higgins SC, Alagbaoso A, Javid T, Polyzoidis S, Ashkan K, Fillmore HL, Pilkington GJ** (Portsmouth, United Kingdom)**9.15-9.30** Defective respiratory complex I triggers metabolic reprogramming in cancer cells. **Iommarini L, Kurelac I, Columbaro M, Dusi S, Leone G, Vatrinet R, Gasparre G, Porcelli AM** (Bologna, Italy)**9.30-9.45** Skeletal muscle mitochondrial energy metabolism in cancer cachexia: clinical and mechanistic approaches. **Dolly A, Cournet J, Dumas JF, Servais S** (Tours, France)**9.45-10.00** The heme exporter FLVCR1a modulates cellular redox status and mitochondrial metabolism: implication in colorectal cancer in Burkitt's lymphoma. **Fiorito V, Destefanis F, Marchi S, Medico E, Cancelliere C, Bardelli A, Silengo L, Altruda F, Pinton P, Tolosano E** (Turin, Italy)

Coffee Break (Sala Cagliari)

**SESSION 7. METABOLIC CONTROL OF CANCER BEHAVIOUR I****Pierre Sonveaux P** (Brussels, Belgium)**Georgina D Barnabas** (Tel Aviv, Israel)**8.30-8.45** Limiting nutrient conditions reroute metabolic pathways in tumor cells.**O38** **Otto AM, Gkiouli M, Biechl P, Hintermair J, Eisenreich W** (Garching, Germany)**8.45-9.00** PHGDH and psat confer metabolic vulnerability to IDH2-driven**O39** reprogramming in breast cancer. **Barnabas G, Michal H, Joo SL, Yair P, Livnat JA, Saverio T, Eyal G, Eytan R, Tamar G** (Tel Aviv, Israel)Conference rooms  
for DAY 2> 8.30 Session 6:  
Sala del Museo> 8.30 Session 7:  
Sala Affrescata> 10.00 Poster  
session: Sala-  
Polivalente> 11.30 H2020  
Match Making  
Event: Sala  
Polivalente> 13.30 Meet-the-  
professor ses-  
sion: Sala Poli-  
valente> 15.00 ISCaM  
Assembly:  
Chiesa> 16.30 Session 8:  
Sala del Museo> 16.30 Session 9:  
Sala Affrescata

[www.iscams.org](http://www.iscams.org)Conference rooms  
for DAY 2> 8.30 Session 6:  
Sala del Museo> 8.30 Session 7:  
Sala Affrescata> 10.00 Poster  
session: Sala  
Polivalente> 11.30 H2020  
Matchmaking  
Event: Sala  
Polivalente> 13.30 Meet-the-  
professor ses-  
sion: Sala Poli-  
valente> 15.00 ISCaM  
Assembly:  
Chiesa> 16.30 Session 8:  
Sala del Museo> 16.30 Session 9:  
Sala Affrescata

9.00-9.15 Methylglyoxal, a glycolysis side-product, increases the metastatic potential of human breast cancer cells. **Nokin MJ, Durieux F, Bellier J, Gabriel M, Peulen O, Christine M, Charlotheaux B, van Laere S, Roncarati P, Herfs M, Lambert C, Colige A, Caers J, Castronovo V, Bellahcène A** (*Liège, Belgium*)

9.15-9.30 OXPPOS inhibition and PPP induction are early events priming preneoplastic lesions toward HCC development. **Kowalik MA, Gozzo G, Morandi M, Perra A, Menegon S, Giordano S, Gramantieri L, Chiarugi P, Rasola A, Columbano A** (*Cagliari, Italy*)

9.30-9.45 Involvement of P2X7, a membrane receptor for ATP, in the invasive properties of mammary cancer cells. **Brisson L, Jelassi B, Chamouton J, Couillin I, Gombault A, Frank PG, Jiang L-H, Chevalier S, Besson P, Roger S** (*Tours, France*)

9.45-10.00 High levels of lactate enhance pyruvate carboxylase-dependent anaplerosis in MCF-7 cells growing under precarious nutrient conditions. **Gkiouli M, Biechl P, Hintermair J, Eisenreich W, Otto AM** (*Garching, Germany*)

Coffee Break (Sala Cagliari)

**10.00-11.30 POSTER SESSION****11.30-12.30 H2020 MATCHMAKING EVENT**

Lunch (Caffetteria)

**13.30-14.30 MEET-THE-PROFESSOR SESSION****14.30-15.00 INDUSTRY SYMPOSIUM****15.00-16.00 ISCaM ASSEMBLY**

Coffee Break (Sala Cagliari)

**SESSION 8. TARGETING OF MITOCHONDRIA AND METABOLISM****Giuseppe Gasparre** (*Bologna, Italy*)**Deborah Grasso** (*Brussels, Belgium*)

16.30-16.45 Targeting respiratory complex I causes HIF1A destabilization in cancer cells and activates stroma-mediated angiogenesis. **Kurelac I, Vatrinet R, Iommarini L, Amato L, Vidone M, De Luise M, Giulia L, Girolimetti G1, Vidali S, Ragazzi M, Columbaro M, Gibellini L, Ombrato L, Cosarizza A, Kofler B, Malanchi I, Porcelli AM, Gasparre G** (*Bologna, Italy*)

16.45-17.00 Effects of mitochondrial calcium uniporter modulators on cells growth and migration. **De Mario A, Tosatto A, Mammucari C, Rizzuto R** (*Padua, Italy*)

Conference rooms  
for DAY 2

- > 8.30 Session 6:  
Sala del Museo
- > 8.30 Session 7:  
Sala Affrescata
- > 10.00 Poster  
session: Sala  
Polivalente
- > 11.30 H2020  
Matchmaking  
Event: Sala  
Polivalente
- > 13.30 Meet-the-  
professor Ses-  
sion: Sala Poli-  
valente
- > 15.00 ISCaM  
Assembly:  
Chiesa
- > 16.30 Session 8:  
Sala del Museo
- > 16.30 Session 9:  
Sala Affrescata

17.00-17.15 Celecoxib inhibits mitochondrial O<sub>2</sub> consumption, promoting superoxide production and causing extensive apoptosis of metastatic cancer cells. **O46** Pritchard R, Rodríguez-Enríquez S, Pacheco-Velázquez SC, Bortnik V, Moreno-Sánchez R, Ralph S (*Gold Coast, Australia*)

17.30-17.45 Inhibition of mitochondrial substrate-level phosphorylation kills glutaminolytic cancer cells. **O47** Doczi J, Horvath G, Flores R, Brown A, Seyfried T2, Tretter L, Adam-Vizi V, Chinopoulos C (*Budapest, Hungary*)

17.45-18.00 Mitochondrial and glycolytic inhibitors hamper cancer viability and enhance response to conventional chemotherapy. **O48** Valente D, Granja S, Baltazar F, Queirós O (*Braga, Portugal*)

18.00-18.15 The oncogenic role of the mitochondrial chaperone TRAP1. **O49** Rasola A (*Padua, Italy*)

## Social Event

**SESSION 9. METABOLIC CONTROL OF CANCER BEHAVIOUR II**

**Paolo Porporato** (*Turin, Italy*)

**Lindsay A Broadfield LA** (*Hamilton, Canada*)

16.30-16.45 A novel ensemble approach to providing small molecule support for validation of cellular targets confirms that glycolysis inhibition is a viable antiproliferative strategy in leukemic cells. **O50** Zweifach A (*Storrs, USA*)

16.45-17.00 Targeting breast cancer cell survival and migration through inhibition of hexosamine biosynthetic pathway. **O51** Ricciardiello F, Votta G, Palorini R, Tinelli F, Raccagni I, Brunelli L, Pastorelli R, Moresco RM, Chiaradonna F (*Milan, Italy*)

17.00-17.15 Integrated control of metabolism by EGFR-PDK1 dependent signaling. **O52** Velpula KK, Guda MR, Asuthkar S, Tsung AJ (*Peoria, USA*)

17.15-17.30 The tumor suppressor KLOTHO: a master regulator of metabolism in breast cancer. **O53** Riva S, Tammi R, Tali S, Ido W, Tamar R (*Tel Aviv, Israel*)

[Sprint Bioscience Travel Grant](#)

17.55-18.00 The gut microbiome as a mediator of metformin's anti-cancer effects. **O54** Broadfield LA, Tsakiridis T, Muti P, Schertzer JD, Steinberg GR (*Hamilton, Canada*)

[Agilent Travel Grant](#)

18.00-18.15 Mitochondrial subtypes of luminal breast cancer have different carbon source preference. **O55** Bentham RB, Menegollo M, Esculier C, Agarwal S, Ren Z, Pignataro V, Bryson K, Stein R, Yuneva M, Szabadkai G (*London, United Kingdom*)

## Social Event

8.30-9.00 **Keynote lecture.** Tumor heterogeneity: the key advantages of single-cell analysis. **Dominique Heymann** (*Sheffield, United Kingdom*)

### SESSION 10. IMAGING OF CANCER METABOLISM

**Valery Khramtsov** (*Morgantown, USA*)

**Giuseppe Ferrauto** (*Turin, Italy*)

9.00-9.15 Interstitial inorganic phosphate as a tumor microenvironment metabolic marker for tumor progression and aggressiveness. **Khramtsov VV, Bobko AA, Eubank TD, Evans J, Dikov MM** (*Morgantown, USA*)

9.15-9.30 Multiparametric magnetic resonance imaging study of murine prostate cancer. **Ferrauto G, Di Gregorio E, Lanzardo S, Manuela I, Ciolli L, Aime S** (*Turin, Italy*) Promega Travel Grant

9.30-9.45 Glioblastoma pH mapping by using Yb-HPDO3A CEST MRI probe. **O58 Ferrauto G, Di Gregorio E, Gimenez U, Auboiron V, Berger F, Aime S, Lahrech H** (*Turin, Italy*)

9.45-10.00 Parahydrogen hyperpolarized pyruvate for metabolic studies on breast cancer cell. **O59 Cavallari E, Carrera C, Aime S, Reineri F** (*Turin, Italy*)

10.00-10.15 Combined in vivo imaging of hypoxia and ph reveals a lack of spatial correlation in a breast tumor murine model. **O60 Anemone A, Consolino L, Bracesco M, Aime S, Longo D** (*Turin, Italy*)

10.15-10.30 Multiparameter profiling of metabolic tumor microenvironment (tme) using paramagnetic probes for evaluation of tme stress, immunosuppressive and metastatic potential and approaches for tme modulation. **O61 Evans J, Bobko A, Cole S, Tchekneva E, Chekneva I, Akhter A, Antonucci A, Carbone DP, Samouilov A, Castro J, Khramtsov V, Dikov M** (*Columbus, USA*)

Coffee Break (Sala Polivalente)

### SESSION 11. CANCER METABOLISM AND DRUG RESISTANCE

**Monica Montopoli** (*Padua, Italy*)

**Luca Zampieri** (*Padua, Italy*)

11.00-11.15 Dissecting the role of mitochondrial genetics and metabolism in cancer cells sensitivity to chemotherapeutic drugs. **O62 Girolimetti G, Guerra F, Kurelac I, Iommarini L, Mastropasqua F, Amato LB, De Luise M, Leone G, Bucci C, Shoshan M, Porcelli AM, Gasparre G** (*Bologna, Italy*)

Conference rooms  
for DAY 3

> 8.30 Keynote  
lecture: Chiesa

> 9.00 Session 10:  
Chiesa

> 11.00 Session  
11: Chiesa

> 12.30 Closure:  
Chiesa



- > 8.30 Keynote lecture: Chiesa
- > 9.00 Session 10: Chiesa
- > 11.00 Session 11: Chiesa
- > 12.30 Closure: Chiesa

**11.15-11.30** Estrogen receptor activating mutations confer an aggressive phenotype to endocrine resistance breast cancer cells through alteration of tumor metabolism. **Lotem Z, Keren ML, Tomer B, Metsada PC, Tamar R, Ido W** (*Tel Aviv, Israel*)

Promega Travel Grant

**11.30-11.45** Cisplatin chemoresistance in ovarian cancer is associated to increased glutamine uptake. **Zampieri L, Grasso D, Montopoli M, Sonveaux P** (*Padua, Italy*)

**11.45-12.00** Nicotinamide phosphoribosyltransferase (nampt) is up-regulated by BRAF-inhibitor-resistant melanoma cells, becoming an actionable therapeutic target. **Audrito V, Managò A, La Vecchia S, Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C, Stingi A, Arruga F, Vaisitti T, Massi D, Mandalà M, Raffaelli N, Deaglio S** (*Turin, Italy*)

Agilent Travel Grant

**12.00-12.15** Oxidative metabolism confers intrinsic radioresistance to SQD9 human head and neck cancer cells. **Grasso D, Danhier P, Bol V, Grégoire V, Sonveaux P** (*Brussels, Belgium*)

**12.15-12.30** Medium chain triglyceride supplemented ketogenic diet enhances anti-tumor and anti-angiogenic efficacy of chemotherapy on murine neuroblastoma xenografts. **Aminzadeh-Gohari S, Feichtinger RG, Vidali S, Locker F, Rutherford T, O'Donnel M, Stöger-Kleiber A, Mayr JM, Sperl W, Kofler B** (*Salzburg, Austria*)

## CLOSURE

*Nicola Baldini (Bologna, Italy)*

**12.30-13.00** **Closing lecture** – Nutrients, genes and metabolism in cancer.  
**Antonio Moschetta** (Bari, Italy)

**13.00-13.15** Closing

Lunch Buffet (Sala Polivalente)

Departure

